Tuesday , 25 June 2019
Breaking News

Tag Archives: zydus

NCLT approves amalgamation of Zydus Wellness’ two subsidiaries

National Company Law Tribunal (NCLT), Bench at Ahmedabad has given an approval to Zydus Wellness for the Scheme of Amalgamation (Scheme) between two subsidiaries, Heinz India (Heinz) with Zydus Nutritions (ZNL). Upon amalgamation, Heinz has ceased to be in existence and also to be the subsidiary of the company. The effective date of the Scheme is May 24, 2019. Zydus ... Read More »

Zydus Cadila receives USFDA’s approval for Leflunomide Tablets

Zydus Cadila has received the final approval from the United States Food & Drug Administration (USFDA) to market Leflunomide Tablets USP (US RLD-Arava Tablets), 10 mg and 20 mg. It will be manufactured at the group’s formulations manufacturing facility at Baddi. This medication is used to treat rheumatoid arthritis, a condition affecting multiple small and large joints of the body. ... Read More »

Zydus Cadila receives final USFDA’s nod for Atenolol and Chlorthalidone Tablets

Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Atenolol and Chlorthalidone Tablets USP (US RLD-Tenoretic), 50 mg/25 mg and 100 mg/25 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. This medication is used to treat high blood pressure (hypertension). Lowering high blood pressure helps prevent ... Read More »

Zydus Cadila gets USFDA’s final nod for Triamterene, Hydrochlorothiazide Capsules

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Triamterene and Hydrochlorothiazide Capsules USP (US RLD-DYAZIDE), 37.5 mg/25 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. The fixed dose combination of Triamterene and Hydrochlorothiazide is indicated for the treatment of hypertension or edema in patients ... Read More »

Zydus Wellness gets approval to raise Rs 1,500 crore via NCDs

Zydus Wellness has received approval to raise funds of aggregate nominal value up to Rs 1,500 crore through issuance of rated, secured, listed, redeemable, Non-Convertible Debentures (NCDs) each having a face value of Rs 10 lakh on private placement basis. The Board of Directors of the Company at its meeting held on January 11, 2019 has approved the same. Zydus ... Read More »

Zydus receives approval from USFDA for Clindamycin Phosphate and Benzoyl Peroxide Gel

Zydus Cadila has received the final approval from the USFDA to market Clindamycin Phosphate and Benzoyl Peroxide Gel, (US RLD-DUAC Gel), 1.2%/5%. It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad. This combination medication is used to treat a certain type of acne (inflammatory acne vulgaris). It helps to decrease the number of acne pimples. Clindamycin is ... Read More »

Zydus Cadila gets USFDA’s approval for Nystatin and Triamcinolone Acetonide Ointment

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Nystatin and Triamcinolone Acetonide Ointment USP, (US RLD -Mycolog-II Ointment), 100,000 units/gram and 1 mg/gram. It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad. It is used to treat fungal skin infections. This product contains nystatin, an anti-fungal drug ... Read More »